- Conditions
- Cataract
- Interventions
- Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion
- Drug
- Lead sponsor
- Cathleen McCabe MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bradenton, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
- Interventions
- Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
- Drug
- Lead sponsor
- Edward J. Holland
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug · Other
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Dry Eye Disease
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Cataracts, Inflammation
- Interventions
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Keratitis Bacterial
- Interventions
- Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
- Drug · Other
- Lead sponsor
- Thomas M. Lietman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Miami, Florida
- Conditions
- Herpes Simplex Virus Keratitis
- Interventions
- oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Endogenous Anterior Uveitis
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Uveitis
- Interventions
- Difluprednate, Prednisolone Acetate
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- New Albany, Indiana
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug · Other
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida